Dulaglutide
Diabetes Mellitus Type 2
Indicated as once-weekly SC injection adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM)
It is also indicated to reduce risk of major adverse cardiovascular (CV) events (CV death, nonfatal MI, or nonfatal stroke) in adults with T2DM who have established CV disease or multiple CV risk factors
Initial: 0.75 mg SC once weekly
May increase dose to 1.5 mg once weekly for additional glycemic control
If additional glycemic control needed, increase to 3 mg once weekly after at least 4 weeks on the 1.5-mg dose
If additional glycemic control needed, increase to maximum dose of 4.5 mg once weekly after at least 4 weeks on the 3-mg dose
Dosage Modifications
Renal impairment (any severity): No dosage adjustment required
Hepatic impairment (any severity): No dosage adjustment required; owing to limited data, caution advised
Dosing Considerations
Not recommended as first-line therapy for patients inadequately controlled on diet and exercise
Has not been studied with a history of pancreatitis; consider another antidiabetic therapy
Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis
Not for patients with preexisting severe GI disease